FMS

The Week

XLV.US rose 1.45% this week to close at $179.28, while the S&P 500 fell 0.47%, leaving the ETF ahead by roughly 1.92 percentage points. Day by day, the fund opened Monday at $175.72, dipped to a weekly low of $175.27, and settled at $175.65. It then pushed higher for three straight sessions, topping out at $182.25 on Thursday before closing that day at $181.30. Friday gave back some gains to end at $179.28. Weekly amplitude was 3.97%, with average daily volume of 8.10m shares, about 5.6% above the 60-day median. The pattern was a choppy advance that faded into the close.

Sector News

Healthcare news this week clustered around clinical data, M&A, and a spinoff. An AstraZeneca-Amgen asthma drug hit 69% remission in an esophageal disease trial, and positive Phase 3 results for Tezspire sent Amgen to a record high. Merck and Moderna’s cancer vaccine combination cut the risk of death or recurrence in melanoma by more than 40%, though an embargo breach rattled investors and knocked Moderna’s stock lower. Gilead agreed to buy PepStar’s IL-23R inhibitor programme for $1.28bn upfront, adding an oral inflammatory bowel disease candidate. Abbott reported a 44% year-on-year drop in third-quarter net earnings and announced plans to spin off its nutrition business, sending shares down. Thermo Fisher beat revenue and adjusted profit estimates with 6% organic growth, but the divergence among heavyweight components kept the ETF in a push-pull.

The Week Ahead

Macro data arrives in force next week. Dallas Fed manufacturing activity is due on 26 October, and 27 October brings durable goods orders, FHFA house prices, the Case Shiller 20-city index, new home sales, the Richmond Fed composite index, and consumer confidence. On the healthcare side, several threads from this week are worth tracking: the market’s follow-through after Moderna’s cancer vaccine data becomes fully public, Gilead’s integration plans for the PepStar programme, and Abbott’s capital structure following its nutrition spinoff.

In Short

XLV.US advanced this week even as the broader market slipped, supported by positive clinical readouts and deal activity, though negative reactions in names like Abbott and Moderna showed the sector is not moving in one direction. Valuation stands at 18x P/E and 1.39x P/B, while the latest session’s flow data show large-lot money leaning net seller and small/medium orders leaning net buyer. The picture is one of firm sector sentiment alongside event-driven stock volatility and a divided flow structure. The question now is whether next week’s macro releases sustain risk appetite and whether the clinical follow-through gives the sector a clearer direction.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.